Cette page a été traduite automatiquement et l'exactitude de la traduction n'est pas garantie. Veuillez vous référer au version anglaise pour un texte source.

Traitement endoscopique du HCRN par rapport au traitement shunt de l'hydrocéphalie chez les nourrissons (ESTHI)

22 septembre 2026 mis à jour par: John Kestle, University of Utah

Traitement endoscopique versus shunt de l'hydrocéphalie chez les nourrissons

Hydrocephalus is a potentially debilitating neurological condition that primarily affects babies under a year of age and has traditionally been treated by inserting a shunt between the brain and the abdomen. A newer endoscopic procedure offers hope of shunt- free treatment that may reduce complications over a child's life, but it is not clear if the endoscopic procedure results in similar intellectual outcome as shunt. Therefore, the investigators propose a randomized trial to compare intellectual outcome and brain structural integrity between these two treatments, to help families make the best treatment decision for their baby.

Aperçu de l'étude

Description détaillée

The ESTHI Trial is a multi-center randomized controlled trial (RCT) comparing endoscopic third ventriculostomy with choroid plexus cauterization (ETV+CPC) and shunt in infants with hydrocephalus. The study will leverage the infrastructure of the Hydrocephalus Clinical Research Network (HCRN), a committed group of 14 leading North American pediatric neurosurgical centers with a long track-record of successful collaborative clinical research and RCTs in hydrocephalus. Optimal cognitive outcome is the primary concern of families and will, therefore, be the primary outcome. Assessment of dMRI, a validated, non-invasive method of measuring white matter microstructural integrity and structural connectivity in the developing brain, will provide further insight into the developmental consequences of these two treatments. The results of the RCT will help families determine the optimal treatment of hydrocephalus for their child.

Type d'étude

Interventionnel

Inscription (Réel)

165

Phase

  • N'est pas applicable

Contacts et emplacements

Cette section fournit les coordonnées de ceux qui mènent l'étude et des informations sur le lieu où cette étude est menée.

Lieux d'étude

    • Alberta
      • Calgary, Alberta, Canada, T3B 6A8
        • Alberta Children's Hospital
    • British Columbia
      • Vancouver, British Columbia, Canada, V6H 3V4
        • British Columbia Children's Hospital
    • Ontario
      • Toronto, Ontario, Canada, M5G 1X8
        • The Hospital for Sick Children
    • Alabama
      • Birmingham, Alabama, États-Unis, 35233
        • Children's of Alabama
    • Arizona
      • Phoenix, Arizona, États-Unis, 85016
        • Phoenix Children's Hospital
    • California
      • Los Angeles, California, États-Unis, 90027
        • Children's Hospital of Los Angeles
    • Colorado
      • Aurora, Colorado, États-Unis, 80045
        • Children's Hospital Colorado
    • Connecticut
      • New Haven, Connecticut, États-Unis, 06520
        • Yale University
    • Florida
      • Jacksonville, Florida, États-Unis, 32207
        • Wolfson Children's Hospital
      • Orlando, Florida, États-Unis, 32806
        • Arnold Palmer Hospital for Children
    • Indiana
      • Indianapolis, Indiana, États-Unis, 46202
        • Trustees of Indiana University
    • Maryland
      • Baltimore, Maryland, États-Unis, 21287
        • Johns Hopkins Children's Center
    • Missouri
      • St Louis, Missouri, États-Unis, 63110
        • St. Louis Children's Hospital
    • Ohio
      • Columbus, Ohio, États-Unis, 43205
        • Nationwide Children's Hospital
    • Pennsylvania
      • Pittsburgh, Pennsylvania, États-Unis, 15224
        • Children's Hospital of Pittsburgh of UPMC
      • University Park, Pennsylvania, États-Unis, 16802
        • The Pennsylvania State University
    • Tennessee
      • Nashville, Tennessee, États-Unis, 37232
        • Monroe Carell Jr. Children's Hospital at Vanderbilt
    • Texas
      • Houston, Texas, États-Unis, 77030
        • Texas Children's Hospital
    • Utah
      • Salt Lake City, Utah, États-Unis, 84118
        • Primary Children's Hospital
    • Virginia
      • Richmond, Virginia, États-Unis, 23284
        • Virginia Commonwealth University
    • Washington
      • Seattle, Washington, États-Unis, 98105
        • Seattle Children's Hospital

Critères de participation

Les chercheurs recherchent des personnes qui correspondent à une certaine description, appelée critères d'éligibilité. Certains exemples de ces critères sont l'état de santé général d'une personne ou des traitements antérieurs.

Critère d'éligibilité

Âges éligibles pour étudier

1 jour à 1 an (Enfant)

Accepte les volontaires sains

Non

Sexes éligibles pour l'étude

Tout

La description

Inclusion Criteria:

  1. Corrected age <104 weeks and 0 days,

    AND

  2. Child is ≥ 37 weeks post menstrual age,

    AND

  3. Child must have symptomatic hydrocephalus, defined as:

    Ventriculomegaly on MRI (frontal-occipital horn ratio (FOR) >0.45, which approximates "moderate ventriculomegaly"), and at least one of the following:

    • Head circumference >98th percentile for corrected age with either bulging fontanelle or splayed sutures
    • Upgaze paresis/palsy (sundowning)
    • CSF leak
    • Papilledema
    • Tense pseudomeningocele or tense fluid along a track
    • Vomiting or irritability, with no other attributable cause
    • Bradycardias or apneas, with no other attributable cause
    • Intracranial pressure (ICP) monitoring showing persistent elevation of pressure with or without plateau waves

    AND

  4. No prior history of shunt insertion or endoscopic third ventriculostomy (ETV) procedure (previous temporization devices and/or external ventricular drains permissible)

Exclusion Criteria:

  1. Hydrocephalus due to intraventricular hemorrhage in a child born before 37 weeks gestational age; OR

  2. Anatomy not suitable for ETV+CPC or anteriorly placed ventriculoperitoneal shunt defined as:

    • Moderate to severe prepontine adhesions on steady state free precession (SSFP) or T2 weighted fast (turbo) spin echo (FSE/TSE) MRI, which includes the following sequences: FIESTA, FIESTA-C, TrueFISP, CISS, Balanced FFE (bFFE), CUBE, SPACE, VISTA, IsoFSE, and 3D MVOX
    • Closure of one or both foramina of Monro
    • Thick floor of third ventricle (≥ 3mm)
    • Narrow third ventricle (<5mm)
    • Presence of scalp, bone, or ventricular lesions that make placement of an anterior shunt impracticable; OR
  3. Underlying condition with a high chance of mortality within 12 months; OR

  4. Hydrocephalus with loculated CSF compartments; OR

  5. Peritoneal cavity not suitable for distal shunt placement; OR

  6. Active CSF infection; OR

  7. Hydranencephaly; OR

  8. Child requires an intraventricular procedure (e.g. endoscopic biopsy) in addition to the initial first-time permanent procedure for the treatment of hydrocephalus.

Plan d'étude

Cette section fournit des détails sur le plan d'étude, y compris la façon dont l'étude est conçue et ce que l'étude mesure.

Comment l'étude est-elle conçue ?

Détails de conception

  • Objectif principal: Traitement
  • Répartition: Randomisé
  • Modèle interventionnel: Affectation parallèle
  • Masquage: Aucun (étiquette ouverte)

Armes et Interventions

Groupe de participants / Bras
Intervention / Traitement
Comparateur actif: ETV+CPC

Subjects randomized to this arm will undergo an ETV+CPC procedure for treatment of Hydrocephalus

Since the early 1990s, ETV has become the main alternative to shunting for hydrocephalus. This procedure involves placing an endoscopic camera into the ventricles of the brain and creating a hole in the floor of the third ventricle to act as an internal bypass for obstructed CSF. The cauterization of choroid plexus (CPC) involves the use of a device to burn or cauterize tissue from the choroid plexus. The choroid plexus of the brain exists in the lateral ventricles, the third ventricle, and the fourth ventricle. Its main role is the production of CSF. The success of ETV alone is poor in infants, but when combined with CPC, improved results have been observed and ETV+CPC has become a safe viable option for these children.

Comparateur actif: Ventriculoperitoneal Shunt

Subjects randomized to this arm will undergo a Ventriculoperitoneal Shunt procedure for treatment of Hydrocephalus

The most common treatment for hydrocephalus has been the insertion of a ventriculoperitoneal shunt, which has been in popular use for over 50 years. This consists of silastic tubing attached to a valve mechanism that runs subcutaneously from the head to the abdomen. It is one of the most common procedures performed by pediatric neurosurgeons.

Que mesure l'étude ?

Principaux critères de jugement

Mesure des résultats
Description de la mesure
Délai
Bayley Scale of Infant Development-IV (Bayley-IV) Cognitive Scale score
Délai: 12 months post randomized surgical intervention

The primary objective is to determine, in infants <104 weeks corrected age, with hydrocephalus requiring treatment at tertiary care pediatric neurosurgery centers in North America, if treatment with ETV+CPC compared to shunt results in non-inferior cognitive outcome at 12 months from surgery, as measured by Bayley-IV Cognitive Scale score with a non-inferiority margin of 1.5. Scaled scores range from 1-19. Higher scores indicate better outcomes. Scores will also be obtained at 3 and 5 years of age.

12 months post randomized surgical intervention

Mesures de résultats secondaires

Mesure des résultats
Description de la mesure
Délai
Bayley Scale of Infant Development-IV (Bayley-IV) Language Scaled Score
Délai: 12 months post randomized surgical intervention

To determine, in the same cohort of infants, if ETV+CPC compared to shunt results in non-inferior Bayley-IV Language Scaled scores. Scaled scores range from 1-19. Higher scores indicate better outcomes.

12 months post randomized surgical intervention
Bayley Scale of Infant Development-IV (Bayley-IV) Motor Scaled Score
Délai: 12 months post randomized surgical intervention

To determine, in the same cohort of infants, if ETV+CPC compared to shunt results in non-inferior Bayley-IV Motor Scaled scores. Scaled scores range from 1-19. Higher scores indicate better outcomes.

12 months post randomized surgical intervention

Autres mesures de résultats

Mesure des résultats
Description de la mesure
Délai
Vineland-3 Communication Domain Score
Délai: 12 months post randomized surgical intervention

To determine, in the same cohort of infants, if ETV+CPC compared to shunt results in non-inferior Vineland-3 Communication Domain scores. Domain scores range from 20-140. Higher scores indicate better outcomes.

12 months post randomized surgical intervention
Vineland-3 Daily Living Skills Domain Score
Délai: 12 months post randomized surgical intervention

To determine, in the same cohort of infants, if ETV+CPC compared to shunt results in non-inferior Vineland-3 Daily Living Skills Domain scores. Domain scores range from 20-140. Higher scores indicate better outcomes.

12 months post randomized surgical intervention
Vineland-3 Socialization Domain Score
Délai: 12 months post randomized surgical intervention

To determine, in the same cohort of infants, if ETV+CPC compared to shunt results in non-inferior Vineland-3 Socialization Domain scores. Domain scores range from 20-140. Higher scores indicate better outcomes.

12 months post randomized surgical intervention
Vineland-3 Motor Skills Domain Score
Délai: 12 months post randomized surgical intervention

To determine, in the same cohort of infants, if ETV+CPC compared to shunt results in non-inferior Vineland-3 Motor Skills Domain scores. Domain scores range from 20-140. Higher scores indicate better outcomes.

12 months post randomized surgical intervention
Vineland-3 Adaptive Behavior Composite Score
Délai: 12 months post randomized surgical intervention

To determine, in the same cohort of infants, if ETV+CPC compared to shunt results in non-inferior Vineland-3 Adaptive Behavior Composite (ABC) scores. ABC scores range from 20-140. Higher scores indicate better outcomes.

12 months post randomized surgical intervention
The occurrence of treatment failure.
Délai: Through study completion, a maximum of 7 years.

Treatment failure is defined as obstruction, loculated compartments, overdrainage, CSF infection, or significant intraoperative complication. The rate of occurrence of each type, for the initial procedure, will be calculated. Failure can be captured at anytime during the course of the 7 year study. Occurrence between treatment arms will be compared.

Through study completion, a maximum of 7 years.
Time to failure.
Délai: Through study completion, a maximum of 7 years

Time to failure is the number of days in which the intervention is functionally successful. It is calculated from date of surgery to date of failure, as described in Outcome 9. Time to failure between treatment arms will be compared.

Through study completion, a maximum of 7 years
Total number of hospital admission days within 12 months after surgery
Délai: 12 months post randomized surgical intervention

Number of days subject is admitted to the hospital during the first 12 months following the initial surgical intervention. All hospital admissions included, regardless of reason for admission. Number of hospital admission days between treatment arms will be compared.

12 months post randomized surgical intervention
Total number of repeat surgeries within 12 months after surgery
Délai: 12 months post randomized surgical intervention

Number of shunt and ETV+CPC procedures during the first 12 months following the initial surgical intervention. Number of repeat surgeries between treatment arms will be compared.

12 months post randomized surgical intervention
Total number of brain imaging (CT, MRI, ultrasound) scans within 12 months after surgery
Délai: 12 months post randomized surgical intervention

Number of CT, MRI, and ultrasound brain scans during the first 12 months following the initial surgical intervention. Total imaging between treatment arms will be compared.

12 months post randomized surgical intervention
All major peri-operative and post-operative complications
Délai: Through study completion, a maximum of 7 years

Number of peri-operative and post-operative complications to include those related to CSF circulation, infection, hemorrhage, seizures, and new neurological deficits. Number of complications between treatment arms will be compared.

Through study completion, a maximum of 7 years
Brain and ventricle volume on MRI performed at 12 months after surgery
Délai: 12 months post randomized surgical intervention

Brain and CSF volumes will be converted to Z-scores based on previously described age- and sex-adjusted distributions and used for comparison of brain volume and growth between ETV+CPC and shunt treatment groups.

12 months post randomized surgical intervention
dMRI corpus collosum (CC) and corticospinal tract (CST) fractional anisotropy (FA) at 12 months after surgery.
Délai: 12 months post randomized surgical intervention

Develop dMRI maps, including fractional anisotropy (FA), mean diffusivity (MD), axial diffusivity (AD), and radial diffusivity (RD). Tract-based spatial statistics (TBSS) will be used for voxel-wise analyses of white matter tracts. Maps will be used to compare cerebral structural connectivity between the two treatment arms.

12 months post randomized surgical intervention
Cerebral spinal fluid myelin basic protein (MBP) levels measured at the time of ETV+CPC or shunt
Délai: 12 months post randomized surgical intervention

Examine correlations of cerebral spinal fluid myelin basic protein (MBP) levels to post-operative Bayley-IV Cognitive Scale score.

12 months post randomized surgical intervention
Cerebral spinal fluid amyloid precursor protein (APP) levels measured at the time of ETV+CPC or shunt
Délai: 12 months post randomized surgical intervention

Examine correlations of cerebral spinal fluid amyloid precursor protein (APP) to post-operative Bayley-IV Cognitive Scale score

12 months post randomized surgical intervention
Cerebral spinal fluid NCAM-1 levels measured at the time of ETV+CPC or shunt
Délai: 12 months post randomized surgical intervention

Examine correlations of cerebral spinal fluid NCAM-1 levels to post-operative Bayley-IV Cognitive Scale score

12 months post randomized surgical intervention
Cerebral spinal fluid glial fibrillary acid protein (GFAP) levels measured at the time of ETV+CPC or shunt
Délai: 12 months post randomized surgical intervention

Examine correlations of cerebral spinal fluid glial fibrillary acid protein (GFAP) to post-operative Bayley-IV Cognitive Scale score

12 months post randomized surgical intervention
Wechsler Preschool & Primary Scale of Intelligence (WPPSI) Scores
Délai: At 5 years of age

To determine, in infants who reach 5 years of age before the end of the study, if ETV+CPC compared to shunt results in non-inferior WPPSI scaled scores. Scaled scores range from 1-19. Higher scores indicate better outcomes.

At 5 years of age
Health related quality of life (HRQoL) measurements
Délai: 12 months post randomized surgical intervention, and at 3 and 5 years of age

To compare health-related quality of life (HRQoL), as measured by vi-sual analogue scales (VAS), Health Utilities Preschool (HuPS), and the Hydrocephalus Outcome Questionnaire (HOQ), between treatment arms.

12 months post randomized surgical intervention, and at 3 and 5 years of age

Collaborateurs et enquêteurs

C'est ici que vous trouverez les personnes et les organisations impliquées dans cette étude.

Dates d'enregistrement des études

Ces dates suivent la progression des dossiers d'étude et des soumissions de résultats sommaires à ClinicalTrials.gov. Les dossiers d'étude et les résultats rapportés sont examinés par la Bibliothèque nationale de médecine (NLM) pour s'assurer qu'ils répondent à des normes de contrôle de qualité spécifiques avant d'être publiés sur le site Web public.

Dates principales de l'étude

Début de l'étude (Réel)

21 juillet 2020

Achèvement primaire (Estimé)

30 mai 2027

Achèvement de l'étude (Estimé)

31 août 2027

Dates d'inscription aux études

Première soumission

27 octobre 2019

Première soumission répondant aux critères de contrôle qualité

22 novembre 2019

Première publication (Réel)

26 novembre 2019

Mises à jour des dossiers d'étude

Dernière mise à jour publiée (Réel)

25 septembre 2026

Dernière mise à jour soumise répondant aux critères de contrôle qualité

22 septembre 2026

Dernière vérification

1 septembre 2026

Plus d'information

Termes liés à cette étude

Plan pour les données individuelles des participants (IPD)

Prévoyez-vous de partager les données individuelles des participants (DPI) ?

OUI

Description du régime IPD

After subject enrollment and 5 year follow up have been completed, we will prepare a final study database for analysis. A releasable database will be produced and completely de-identified in accordance with the definitions provided in the Health insurance Portability and Accountability Act (HIPAA). Namely, all identifiers specified in HIPAA will be recoded in a manner that will make it impossible to deduce or impute the specific identity of any patient. The database will not contain any institutional identifiers. We will also prepare a data dictionary that provides a concise definition of every data element included in the database. If specific data elements have idiosyncrasies that might affect interpretation or analysis, this will be discussed in the dictionary document.

In accordance with policies determined by the investigators and funding sponsors, the releasable database will be provided to users in electronic form.

Délai de partage IPD

Within one year of primary publication or within 18 months of the last study visit of the last subject, whichever occurs first.

Type d'informations de prise en charge du partage d'IPD

  • PROTOCOLE D'ÉTUDE
  • SÈVE

Informations sur les médicaments et les dispositifs, documents d'étude

Étudie un produit pharmaceutique réglementé par la FDA américaine

Non

Étudie un produit d'appareil réglementé par la FDA américaine

Non

Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .

S'abonner